Enhertu continues to demonstrate durable responses with new data from DESTINY-Breast01 in HER2-positive metastatic breast cancer
Median duration of response exceeded 20 months Update shows encouraging landmark survival in exploratory analysis with an estimated three out of four patients alive at 18 monthsUpdated results from the positive DESTINY-Breast01 Phase II trial showed AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) continued to demonstrate impressive efficacy and durable responses in patients with HER2-positive metastatic breast cancer following two or more prior HER2-based regimens. The updated data were presented in a Spotlight Poster Discussion at